Introduction
Pain is an unpleasant sensation primarily designed to avoid tissue damage. Pain is considered a disease that needs aggressive physician treatment. Remarkably, the number of patients suffering pain has been increasing up to half a billion cases per year, having a tremendous impact on many quality-of-life measures (1) . Undertreated or poorly treated pain is debilitating, and results in loss of work, productivity, family crisis, depression and/or suicide (2, 3) . Currently, it is estimated that at least 50% of individuals seeking treatment are unsatisfied with their present pain management options. Thus, the economic and medical costs of inadequate pain therapy in the community are vast.
Although pain has been traditionally considered as a unique and homogeneous pathology, cumulative progress has established that pain is an extremely complex and dynamic process involving multiple, interrelated neurotransmitter/neuromodulator systems in the peripheral nervous system. Indeed, as many as 15 neurotransmitters have been implicated in diverse aspects of pain-processing pathways (4-6). Two major types of pain are widely recognized, namely neuropathic and inflammatory. Nerve injury due to infection, autoimmune disease, trauma, and viral infections underlie the etiology of neuropathic pain. Damaged fibres ectopically discharge augmenting nerve activity, which induces hyperexcitability at the level of the spinal cord leading to burning-like pain.
At variance with neuropathic pain, inflammatory pain is produced in response to tissue damage (4, 7) . Inflammatory pain involves various painful responses resulting from peripheral tissue injury and/or inflammation produced by trauma, infection, surgery, burns o r diseases with an inflammatory component. In most cases, inflammatory pain is mediated by pro-algesic mediators such as protons, histamine, cytokines, prostaglandins, neurokinins, chemokines and ATP (4, 7) . These molecules sensitise neurons in the pain pathway (known as nociceptive neurons or nociceptors), either by directly modulating the sensitivity of membrane receptors or up-regulating intracellular signalling cascades. Nociceptors are sensitized by activation of both PKC and PKA pathways, which lead to phosphorylation of sensory receptors involved in nociceptive function (8, 9) . As a result, strong sensory signalling is conveyed to the spinal cord and subsequently to specific brain regions leading to pain sensation. This phenomenon is known as peripheral sensitization. In addition, synaptic and metabolic changes at the level of the spinal cord may occur leading to the so-called central sensitization which further augments the pain sensation (4, 6) . A major hallmark of inflammatory pain is thermal and mechanical hyperalgesia. Depending on the duration inflammatory pain is classified as acute or chronic.
The molecular components and mechanisms involved in inflammatory pain transduction are now starting to be unfolded. The identification and cloning of the TRPV1 channel represented a significant step in the clarification of the molecular mechanisms underlying transduction of noxious chemical and thermal stimuli by peripheral nociceptors. There is growing evidence that peripheral sensitization is la rgely mediated by excessive excitation of TRPV1 receptors (10, 11) . Because of its central implication in hyperalgesia, the TRPV1 receptor has emerged as a key therapeutic target for inflammatory pain management.
The TRP receptor family
The Transient Receptor Potential (TRP) gene family is formed by more than 20 different gene products that result in non selective cation channels that play a wide diversity of physiological functions. TRP channels are divided into three subfamilies:
TRPC, TRPV and TRPM that have a common topology of six transmembrane segments 5 (S1-S6) with a pore region between the fifth and sixth segment, and cytoplasmic N-and C-termini. TRPV and TRPC contain two to four ankyrin domains that are thought to interact with the cytoskeleton ( 12) . The first cloned TRP, a TRPC channel from Drosophila resulted essential for visual transduction. In the worm C. elegans, TRPC2 is required for transduction of pheromone-response of vomeronasal neurons [13] `. These are metabotropic receptors that act through G -protein coupled receptors via the phospholipase C pathway releasing Ca 2+ from the endoplasmic reticulum trough inositol receptors (14) . In contrast, the TRPV family are ionotropic receptors activated by noxious stimuli, for instance, TRPV1 gates in response to noxious temperature (≥42ºC, vanilloids, acidic pH, and pro-algesic substances (15 Immuno-specific staining of TRPV1 has been observed in the plasma membrane, Golgi and small clear vesicles (19) . This ubiquitous intracellular distribution may be relevant for inflammation-induced sensitization.
TRPV1 is also present in various brain nuclei, as well as in non-neuronal tissues, as exemplified by urinary bladder epithelium, smooth muscle and epidermal keratinocytes (20) (21) (22) . TRPV1 is expressed in most of the afferent nerve fibres in the rodent gastrointestinal tract and some of the vagal afferents, however is still unk nown whether it plays a role in gut sensation. TRPV1 is found not only in afferent fibres within the urinary bladder but also in submucosa, mucosa and epithelial cells lining the bladder (21, 23) . Thus, these observations provide a mechanism for the variety of -dependent outward rectification followed by a long-lasting refractory state (during which the cell does not respond to capsaicin and other stimuli). TRPV1 is also gated at temperatures higher 7 than 42°C. In addition, mild extracellular acidic pH potentiates vanilloid receptor activation by noxious heat and vanilloids, while strong acidic conditions (pH<6) directly activates the channel. A widely held tenet is that vanilloids and acidic pH decrease the threshold for heat activation from noxious to non-noxious temperatures.
Therefore, TRPV1 integrates painful physical and chemical noxious stimuli.
Mice deficient in TRPV1 have been generated to validate TRPV1 as a therapeutic target. Physiological and behavioural studies of the knock out animals indicated a clear role of TRPV1 in thermal hyperalgesia, but not in mechanical hypersensitivity (24, 25) . Intriguingly, a modest contribution of TRPV1 to thermal nociception was observed, perhaps due to developmental over-expression of other TRPV members that contribute to the final phenotype. These studies also showed that TRPV1 gene ablation does not modify neuropathic pain responses. Similar conclusions were reached by using pharmacological tools. In vivo inhibition of TRPV1 activity by non-competitive antagonists attenuated thermal nociception and hyperalgesia, and reduced neurogenic inflammation (26) . Taken together, all these findings illustrate that TRPV1 is a widely expressed neuronal receptor that behaves as a gateway for pain transduction and, in turn, validate this receptor as a key therapeutic target for pain management.
Pharmacology of the TRPV1 receptors
Because of its involvement in the ethiology of inflammatory pain, pharmacological modulation of TRPV1 is a valuable strategy to mitigate pain sensation.
Structure-function studies have revealed that the TRPV1 receptor is a molecular entity with various potential drug binding sites. These properties have prompted the discovery of different kinds of receptor modulators with the hope that they will be of clinical use 8 to treat TRPV1 receptor dysfunction, especially in inflammatory conditions. However, because of the relevant role of this thermosensor in the physiology of nociceptors, complete abrogation of channel activity may lead to unwanted side-effects such as general thermal insensitivity. We next will summarize the efforts undertaken to develop three classes of TRPV1 modulators, namely agonists, competitive antagonists and channel blockers.
TRPV1 agonists
Agonists are molecules that gate the channel. Prolonged exposure of the receptor to the agonist, however, induces its closure by taking the protein to a desensitized state.
Agonist-induced desensitization is dependent of the presence of extracellular Ca resiniferanoids, unsaturated dialdehydes and triprenyl phenols, whose typical representative structures are resiniferatoxin (RTX), isovelleral and scutigeral respectively (27) .
Capsaicin is known to have three functional regions, an aromatic A region, where is optimal a parent homovanillyl (3-methoxy 4 -hydroxybenzyl) group, a B 9 region, known as the ester o amide linker, and the aliphatic C region, where a lipophilic octanyl or p-chlorophenetyl moiety is associated with the highest potency. The homovanillyl motif and amide bond regions contain d ipolar groups, which are implicated in hydrogen bonding interactions. Analysis of the structure-activity relationship of numerous capsaicin analogues suggest that these polar regions are essential for maintaining pungency, which could be alternatively expressed as maintaining the excitation of sensory neurons. In contrast, the aliphatic chain in the C region, which has an optimal chain length of 8-10 carbon atoms, is presumed to interact hydrophobically with its receptors (27) . Although a receptor model has been suggested based on the structure-activity relationships of the capsaicin analogs, structural elements in TRPV1 that confer specific interactions with vanilloids have not been characterized.
Moreover, unlike other ligand-gated channels that produce fast synaptic transmission, vanilloids are known to act on the TRPV1 receptor from the intracellular site (28) .
Recently, a region spanning the third transmembrane domain (S3) in TRPV1 was found to be essential for ligand binding, presumably by hydrophobic interactions with capsaicin (29) . Complementary regions in TRPV1, predominantly those located in both cytosolic tails, have also been implicated in structuring the agonist binding site (28) .
Vanilloid compounds have been considered as potential analgesics and have been extensively used in medicine. Capsacinoids are traditionally indicated for relieving toothache. Capsaicin is a standard ingredient in a variety of over-the-counter drugs used worldwide to relieve muscle ache, as an example of the therapeutic value of the excitation that it provokes. Desensitization to capsaicin has a clear therapeutic potential ameliorating urinary bladder overactivity, uraemic itching associated with renal failure, urinary incontinence and inflammatory bowel disease. Additionally, capsaicin-induced neurotoxicity has already been shown to be useful in the treatment of neuropathic pain such as herpes-zoster related neuropathic pain, diabetic neuropathy, and postmastectomy pain (27) .
A major shortcoming of therapeutic capsaicin is burning sensation and irritation that it produces. Structure-activity relationship studies of vanilloids have led to the development of more potent, orally active, vanilloid-like molecules such as SDZ-249482 and KR-25018. However, these compounds still exhibit irritant side effects.
Thus, a drug with long lasting desensitisation and no pungency promises to be of great clinical value. There are naturally and synthetic non pungent capsaicin analogs, like capsiate, olvanil, glycerol nonivamide, and scutigeral, but their low efficacies prevent their clinical development. However, ongoing clinical trials with resiniferatoxin (RTX) (Fig. 1) , a potent capsaicin analogue isolated from Euphorbia resinifera, indicate that such vanilloids may in fact be useful (27) . have not yet been clearly defined, although structure-activity studies suggest that the C 20 -homovanillic moiety, the C 3 -keto group, and the orthoester phenyl group on ring C are crucial structural elements responsible for the extremely high potency of RTX. RTX is being developed as an ultrapotent sensory neuron desensitising agent for the treatment of urinary urge incontinence and the pain associated with diabetic neuropathy and appears to be superior to capsaicin in terms of its tolerability profile (27) . The unquestionable therapeutic potential of RTX is seriously hampered by its limited availability from natural sources and the complexity of its chemical synthesis, as evidenced by the more than 44 reaction steps required for its total synthesis.
Nonetheless, clinical trials with RTX are currently ongoing.
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TRPV1 endogenous ligands
Because TRPV1 is chemically gated the question of whether there are endogenous substances that gate the channel has emerged. There is cumulative evidence that endogenous vanilloid receptor agonists ('endovanilloids') exist and play a central role in the development inflammatory hyperalgesia. There is no doubt that these agents modulate the sensitivity of vanilloid receptors to thermal stimuli.
The first endogenous compound thought to be an endovanilloid was anandamide, a polyunsaturated fatty acid (N-arachidonoylethanolamine), activating both native and recombinant rat TRPV1 receptors ( Fig. 2 ) (30) . However, anandamide is also considered an endocannabinoid since activates both cannabinoid CB1 and CB2
receptors at lower concentrations than those needed to activate TRPV1.
Capsaicin-like substances are structurally similar to some eicosanoids, particularly those derived from the action of 5-lipoxygenase and 12-lipoxygenase and, indeed, arachidonic acid has been found capable of activating the rat TRPV1, and being most potent 12-hydroperoxy-eicosatetraenoic acid (12-HPETE) and leukotriene B4 (LTB4) (Fig. 2) (31) . The binding site on TRPV1 is believed to occur, only by slow, passive diffusion. Eicosanoids are believed to function as 'intracellular endovanilloids', acting at TRPV1 receptors in the cells where they are synthesized.
Recent studies have led to the ident ification of another compound, characterized as N-arachidonoyl-dopamine (NADA) proposed to act as a 'brain endovanilloid since relatively abundant in some brain areas where TRPV1 is also present (Fig. 2) 
(32).
NADA is an endogenous a nandamide analogue several times more potent than anandamide on TRPV1, yet still capable of activating CB1 receptors. Thus, the identification and characterization of endovanilloids may provide important clues to the development of innovative analgesic and anti-inflammatory drugs.
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TRPV1 antagonists
Competitive and non-competitive vanilloid antagonists are the two major classes of TRPV1 modulators being explored for therapeutic exploitation. The first class specifically seeks for compounds that bind to the agonist binding site and lock the channel in the closed, non-conductive state. Non-competitive antagonists, however, interact with additional drug binding sites located on the receptor structure. Of special interest are those acting as open channel blockers because they specifically recognize the overactivated species, i.e. pathological receptors.
TRPV1 competitive antagonists
The first competitive antagonist known, capsazepine was prepared by introducing a saturated seven-membered rigid ring system, which maintained a virtually orthogonal conformation between each N-substituent in the thiourea structure (Fig. 3 ).
Tetrahydrobenzazepine and tetrahydroisoquinoline thiourea derivatives have been prepared as antagonists by the replacement of the p-chlorophenethyl group with 3-acyloxy-2-benzylpropyl groups. All of them are competitive vanilloid antagonists with a potency ranging from 0.2 to 4 µM. When administered in animal models of inflammatory pain these compounds exhibit analgesic activity, although their therapeutic index is still low (33) . In addition, they exhibit limited blockade activity on heat-activated channels present in the neuronal surface.
Recently, a derivative of RTX, 5-Iodo-RTX, was shown to be a highly potent antagonist (IC 50 , 3.9 nM) of TRPV1 (Fig. 3) . This compound exhibits analgesic activity in vivo and is currently in pre-clinical studies. As for RTX, a major drawback is the complexity and cost of its chemical synthesis from RTX, and its limited oral activity (34).
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Taking together, the hunt for better competitive vanilloid antagonists is a major goal of pharmaceutical companies. We should witness in the near future the blossom of these efforts reflected as increasing pipelines of lead compounds for analgesic drug discovery.
TRPV1 non-competitive antagonists
The first non-competitive antagonist introduced as a "functional capsaicin antagonist" was ruthenium red, which is an inorganic polyamine acting as a noncompetitive antagonist that binds to the pore region of the channel (Fig. 4) (27) .
The therapeutic use of ruthenium red is highly precluded because of its unspecific blockade activity.
Arginine rich hexapeptides such as RRRRWW-NH 2 block recombinant TRPV1 channels expressed in Xenopus oocytes with submicromolar efficacy by a noncompetitive way (Fig. 4) (35) . It was recently reported that they may also act through a competitive mechanism (36) . Apart from the specific mechanism, their development as analgesic drugs is prevented by their pharmacological unsafety.
A novel class of non-competitive antagonists of TRPV1 was identified from the screening of a peptidomimetic-based library (26) (Fig. 4) . Peptidomimetic molecules such as N-alkylated glycines (also known as peptoids) constitute a family of non-natural compounds that exhibit interesting biological properties (37) . It presents an affinity for CB1 receptors comparable to that of AEA and also activates TRPV1 receptors more potently than anandamide and capsaicin ( 
Modulators of the TRPV1 receptor signalling complex.
An emerging concept is that ion channels are not isolated devices in the cell membrane, they are rather components of multiprotein complexes that play a key role in 16 physiology and pathology. These macromolecular assemblies are high order signalling networks that balance external and internal signals giving rise to a response.
Dysfunction of protein networks thus has deleterious consequences. These complexes are composed by a plethora of proteins that include receptor, adaptor, signalling, cytoskeletal and novel proteins. Assigned functions to these synaptic signalling assemblies are the biogenesis, distribution and clustering of receptors and their colocalization with signalling proteins for an efficient transduction of external cues. Thus the synaptic protein complex contains a variety of potential drug targets. The molecular identity and organization of the TRPV1 signalling complex is still elusive. Fastadvancing progress in this arena is uncovering the molecular identity of these elements which, in due turn, will be validated as therapeutic targets for drug intervention.
Because most of these targets are protein complexes, the real challenge ahead would the discovery and development of small molecules that modulate protein-protein interactions, a yet unmet goal of current drug discovery.
Perspective
The unquestionable involvement of the TRPV1 receptor in pain transduction has thrust an interest on the development of antagonists of this neuronal receptor for pain management. This is apparently an easy task for current drug discovery platforms, although the real challenge is to develop antagonists that preserve the physiological activity of TRPV1 receptors while correcting over-active receptors. This is a condition to ensure normal pro-prioceptive and nociceptive responses that represent a safety mechanism to prevent tissue injury. Therefore, physiological constraints have to be included in the development and optimization of TRPV1 receptor antagonists to ensure their clinical utility as pain-killers. 
